Table 2.
Studies on Atropine-Induced Control of Myopic Progression
| Authors | Year | Study Ethnicity | Study Design |
|---|---|---|---|
| Brodstein et al195 | 1984 | United States | Prospective, Atropine 1% vs controls |
| Yen et al196 | 1989 | Taiwan | RCT, Atropine 1% vs cyclopentolate 1% vs controls |
| Chou at el197 | 1997 | Taiwan | Cohort, Atropine 0.5% in myopia ≥ −6.0 D |
| Shih et al198 | 1999 | Taiwan | RCT, Atropine 0.5% vs 0.25% vs 0.1% in 6-13-year-old children |
| Kennedy et al199 | 2000 | United States | Cohort, Post-treatment effects of atropine (median 3.5 years) |
| Hsiao et al200 | 2000 | Taiwan | Myopia Intervention Trial (MIT), Single Vision Lenses vs Multifocal Lenses vs Atropine 0.5% with Multifocal Lenses |
| Lee et al201 | 2006 | Taiwan | Cohort, Atropine 0.5% in myopic school-age children |
| Fan et al202 | 2007 | Hong Kong | Cohort, Atropine 1.0% ointment |
| Liang et al203 | 2008 | Taiwan | RCT, Atropine 0.25% with stimulation of auricular acupoints |
| Fang et al204 | 2010 | Taiwan | Cohort, Atropine 0.025% role in pre-myopic children |
| Wu et al205 | 2011 | Taiwan | Cohort, low concentration Atropine (0.05% −0.1%) |
| Lin et al206 | 2013 | China | Cohort, Atropine 1.0% in myopic anisometropia. |
| Chia et al207 | 2013 | Singapore | Full-field electroretinogram findings in ATOM2 study |
| Cooper et al208 | 2013 | United States | 3+3 study design, to determine highest atropine concentration without clinical symptoms |
| Lin et al209 | 2014 | Taiwan | Cohort, Atropine 0.125% vs Orthokeratology Lenses |
| Cheng et al210 | 2014 | Taiwan | RCT, Atropine 0.125% vs Atropine 0.125% with auricular acupoint stimulation. |
| Li et al211 | 2014 | China | Meta-analysis, Effects of atropine in Asian vs White Children. |
| Chia et al212 | 2014 | Singapore | RCT, double-masked, ocular parameters in 1 year after atropine withdrawal |
| Kumaran et al213 | 2015 | Singapore | RCT, biometric changes in eyes of Atropine 1% vs Placebo |
| Yi et al214 | 2015 | China | RCT, Atropine 1.0% effects in myopic eyes |
| Clark et al215 | 2015 | United States | Cohort, Atropine 0.01% in ethnically diverse, broad-ranged myopic population. |
| Polling et al216 | 2016 | Europe | Effectiveness study, Atropine 0.5% |
| Loughman et al217 | 2016 | United States | Acceptability and tolerance of Atropine 0.1% |
| Kothari et al218 | 2017 | Indian | Cohort, Atropine 1.0% safety and efficacy |
| Wan et al219 | 2018 | Taiwan | Retrospective, Effects of orthokeratology and Atropine (0.125% & 0.025%) |